Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorBlock, Matthew S.en_US
dc.contributorVierkant Robert S.en_US
dc.contributorRambau, Peter F.en_US
dc.contributorWinham, Stacey J.en_US
dc.contributorWagner, Philippen_US
dc.contributorTraficante, Nadiaen_US
dc.contributorToloczko, Aleksandraen_US
dc.contributorTiezzi, Daniel G.en_US
dc.contributorRatan, Florin Andreien_US
dc.contributorSinn, Peteren_US
dc.contributorSieh, Weivaen_US
dc.contributorSharma, Raghwaen_US
dc.contributorRothstein, Joseph H.en_US
dc.contributorRamon y Cajal, Teresaen_US
dc.contributorPaz-Ares, Luisen_US
dc.contributorOszurek, Olegen_US
dc.contributorOrsulic, Sandraen_US
dc.contributorNess, Roberta B.en_US
dc.contributorGoode, Ellen L.en_US
dc.description.abstractObjective To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. Patients and Methods We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong). Results Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P=.04) but was also associated with advanced stage (P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P=.009 and P=.02, respectively). Conclusion Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes. Includes data collected from Ballarat Health Services - L. F Ng.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2018-09-06T06:04:29Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2018-09-06T06:05:02Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2018-09-06T06:05:02Z (GMT). No. of bitstreams: 0 Previous issue date: 2018en
dc.titleMyD88 and TLR4 expression in epithelial ovarian cancer.en_US
dc.typeJournal Articleen_US
dc.bibliographicCitation.titleMayo Clinic Proceedingsen_US
dc.subject.healththesaurusOVARIAN CANCERen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.